Compare ARDX & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | LGIH |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2014 | 2013 |
| Metric | ARDX | LGIH |
|---|---|---|
| Price | $5.80 | $46.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 5 |
| Target Price | $10.65 | ★ $71.13 |
| AVG Volume (30 Days) | ★ 2.7M | 332.3K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.53 |
| Revenue | $398,234,000.00 | ★ $1,788,933,000.00 |
| Revenue This Year | $22.71 | N/A |
| Revenue Next Year | $27.81 | $17.77 |
| P/E Ratio | ★ N/A | $10.34 |
| Revenue Growth | ★ 58.12 | N/A |
| 52 Week Low | $3.21 | $39.70 |
| 52 Week High | $6.78 | $109.87 |
| Indicator | ARDX | LGIH |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 45.21 |
| Support Level | $5.73 | $50.90 |
| Resistance Level | $6.20 | $55.30 |
| Average True Range (ATR) | 0.29 | 2.52 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 57.78 | 32.93 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.